A patient with relapsed or refractory multiple myeloma has previously received two lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide. You are considering early-line monotherapy options in light of this randomized trial.
What does the evidence in this abstract support for a patient like this?
